New Cancer Treatment Approved

FDA Approves Curium's New Targeted Treatment for Adults With Rare Tumors

Curium™ has announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for BEXLUTRY™ lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs. This is the first radioligand equivalent for the treatment of GEP -NETs in adults and is the second radiollectand therapy from Curium™ approved by the FDA. Bexlutry is designed to deliver targeted radiation to GEP/NETs by binding to somatostatin receptors commonly expressed on these tumors. The company's North American Chief Executive Officer, Mike Patterson, said the approval is a defining milestone for Curium as it expands its offering into oncology therapeutics. BEXlutRY is now available for prescribing physicians and patient use. Long-term cumulative radiation exposure is associated with an increased risk for cancer.

Topics